

III. Medication

All the prescription and nonprescription drugs used in previous 2 weeks were checked.

* The drugs were coded by 3-digit therapeutic category numbers according to the Standard Commodity Classification No. of Japan.
Note that the fourth and subsequent digits of a code number were NILS-LSA original codes.

Drugs on nervous system and sensory organ

Agents acting on central nervous system

- 111. General anesthetic
- 112. Hypnotic sedative agent, antianxiety agent
- 113. Antiepileptic agent
- 114. Antipyretic analgesic agent
- 115. Stimulant drug, antihypnotic drug
- 116. Antiparkinson drug
- 117. Antipsychotic drug
- 118. Drugs for common cold
- 119. Other agents acting on central nervous system

Agents acting on peripheral nervous system

- 121. Local anesthetic
- 122. Muscle relaxant
- 123. Agents acting on autonomic nervous system
- 124. Antispasmodic agent
- 125. Antiperspirants
- 126. Other agents acting on peripheral nervous system

Agents acting on sensory organ

- 13100. Ophthalmic solution (others)
- 13111. Ophthalmic solution (for cataract)
- 13121. Ophthalmic solution (pilocarpine)
- 13122. Ophthalmic solution (β blocker)
- 13123. Ophthalmic solution (epinephrine)
- 13124. Ophthalmic solution (other solutions for glaucoma)
- 13131. Ophthalmic solution (steroid)
- 13199. Ophthalmic solution (unknown)
- 132. Agents acting on ear, nose and throat use
- 133. Anti-vertiginous drug
- 134. Other agents acting on sensory organ

Drugs on individual organs

Agents acting on cardiovascular system

- 21101. Digitalis agent
- 21102. Xanthine agent
- 21103. Other inotropic agents
- 21201. β blocker
- 21202. Agents for membrane-stabilizing activity
- 21203. Other antiarrhythmic agents
- 21301. Thiazide diuretics
- 21302. Loop diuretics
- 21303. Potassium sparing diuretics
- 21304. Carbonate dehydratase inhibitor
- 21305. Other diuretics
- 214. Unknown antihypertensive agent
- 21401. ACE inhibitor
- 21402. Ca antagonist
- 21403. Other antihypertensive agents
- 215. Vascular reinforcing agent
- 216. Vasoconstrictor
- 217. Vasodilator
- 218. Antihyperlipidemic agent
- 219. Other agents acting on cardiovascular system

Agents acting on respiratory system

- 221. Respiratory stimulator
- 222. Antitussive agent
- 223. Expectorant
- 224. Antitussive agent and expectorant
- 225. Bronchodilator
- 226. Gargle

229. Other agents acting on respiratory system

Agents acting on alimentary system

- 231. Antidiarrheal agent
- 232. Antiulcerative agent
- 233. Stomachic
- 234. Antacid
- 235. Laxative
- 236. Cholagogue
- 237. Combined digestive agent
- 239. Other agents acting on alimentary system

Hormone drug

- 241. Pituitary hormone drug
- 242. Hormone drug of salivary gland
- 243. Thyroid hormone or parathyroid hormone drug
- 244. Anabolic steroid drug
- 245. Adrenocortical hormone drug
- 246. Androgen drug
- 247. Estrogen or progesterone drug
- 248. Mixed hormone drug
- 249. Other hormone drugs

Agents acting on urogenital system or anus

- 251. Agents acting on urinary system
- 252. Agents acting on genital system
- 253. Uterine constrictor
- 254. Contraceptive
- 255. Agents for hemorrhoids
- 259. Other agents acting on urogenital system or anus

Surface-acting agent

- 261. Integumentary microbicide
- 262. Protective agent for wound
- 263. Pyostatics
- 264. Analgesic, antipruritic, astringent, antiphlogistic (medicine for external application)
- 265. Integumentary parasiticide
- 266. Emollient
- 267. Hair tonic
- 268. Bath liquid
- 269. Other surface-acting agents
- 270. Steroid surface-acting agent

Agents for dental use

- 271. Dental local anesthetic
- 272. Agents for devitalization of the pulp
- 273. Analgesic or sedative for dental use
- 274. Agents for mummification of the pulp
- 275. Agents for pulp capping
- 276. Antibiotics for dental use
- 279. Other agents for dental use
- 290. Other agents for organ system

Drugs on metabolism

Vitamins

- 31101. Vitamin A preparation
- 31102. Vitamin D preparation
- 312. Vitamin B1 preparation
- 313. Vitamin B complex preparation (exclude B1)
- 314. Vitamin C preparation
- 315. Vitamin E preparation
- 316. Vitamin K preparation
- 317. Mixed vitamin preparation
- 319. Other vitamin preparations

Restoratives

- 321. Calcium preparation
- 322. Mineral preparation
- 323. Saccharide preparation
- 324. Organic acid preparation
- 325. Protein or amino acid preparation
- 326. Hormone drug made from some internal organ
- 327. Infant preparation
- 329. Other tonic

Blood substitute

- 331. Blood substitute
- 332. Styptics
- 333. Anticoagulant
- 339. Other blood substitutes

Agents for dialysis

- 341. Agents for hemodialysis
- 342. Agents for peritoneal dialysis
- 349. Other agents for dialysis

Other agents acting on metabolic system

- 391. Agents for liver disease
- 392. Antidote
- 393. Agents for habitual intoxication
- 394. Agents for gout
- 395. Enzyme preparation
- 39600. Insulin
- 39601. Oral antidiabetics
- 397. Agents acting generally on metabolic system
- 399. Unclassified agent acting on metabolic system
- 39911. Calcitonin (elcatonin)
- 39912. Calcitonin (calcitonin salmon)
- 39921. Bisphosphonate (alendronate sodium hydrate)
- 39922. Bisphosphonate (sodium risedronate hydrate)
- 39923. Bisphosphonate (etidronate disodium)
- 39931. Ipriflavone
- 39941. Selective estrogen receptor modulator

Cell activation agent

Cell activation agent

- 411. Chlorophyll agent
- 412. Pigment agent
- 419. Other cell activation agents

Antitumor agent

- 421. Alkylating agent
- 422. Antimetabolite
- 423. Antibiotics for antitumor agent
- 424. Plant component for antitumor agent
- 429. Other antitumor agents

Antiallergic drug

- 441. Antihistaminic agent
- 442. Agents for stimulus therapy
- 443. Agents for nonspecific immunogenicity
- 449. Other antiallergic drugs

Drugs prescribed by a crude drug or a herb medicine

- 510. Crude drug
- 520. Herb medicine
- 590. Other drugs prescribed by a crude drug or herb medicine

Drugs for pathogenic organism

Antibiotics

- 611. Antibiotics against gram-positive bacteria
- 612. Antibiotics against gram-negative bacteria
- 613. Antibiotics against gram-positive and negative bacteria
- 614. Antibiotics against gram-positive bacteria and Mycoplasma
- 615. Antibiotics against gram-positive and negative bacteria, Rickettsia, and Chlamydia
- 616. Antibiotics against acid-fast bacterium
- 617. Antibiotics against fungus
- 619. Other antibiotics

Agents for chemotherapy

- 621. Sulfa agent
- 622. Antituberculous agent
- 623. Anti-leprosy agent
- 624. Synthetic antibiotics
- 625. Antiviral agent
- 626. Other agents for chemotherapy

Biological agent

- 631. Vaccine
- 632. Poison or toxoid
- 633. Antitoxic serum or leptospira serum
- 634. Blood supplements

- 635. Reagents for biological tests
- 636. Mixed biological agent
- 639. Other biological agents

Drugs against parasitic disease

- 641. Protozoicide
- 642. Parasiticide
- 649. Other drugs against parasitic disease

Drugs not for treatment

Dispensing drug

- 711. Diluents
- 712. Ointment base
- 713. Solution
- 714. Corrective, tincture
- 715. Emulsifier
- 719. Other dispensing drugs

Drugs for diagnosis

- 721. X-ray contrast medium
- 722. Reagents for functional tests
- 729. Other drugs for diagnosis

Drugs for public health

- 731. Antiseptic
- 732. Pesticide for prevention of epidemics
- 733. Insect repellent
- 734. Insecticide
- 735. Rodenticide
- 736. Other drugs for public health

Reagents for extracorporeal diagnosis

- 741. Reagents for general tests
- 742. Reagents for blood tests
- 743. Reagents for biochemical tests
- 744. Reagents for immunologic or serologic tests
- 745. Reagents for microbiological tests
- 746. Reagents for histopathological tests
- 747. Radiopharmaceutical for extracorporeal diagnosis
- 749. Other reagents for extracorporeal diagnosis

Drugs not for other treatments

- 791. Adhesive bandage
- 799. Other drugs not for treatment

Narcotics

Alkaloid agent

- 811. Opiate alkaloid agent
- 812. Coca alkaloid agent
- 819. Other alkaloid agents

Non-alkaloid narcotics

- 821. Synthetic narcotic

Unclassifiable drug

- 999. Unclassifiable drug

Prevalence of taking medicine in previous 2 weeks

| | | 40-49yr | | 50-59yr | | 60-69yr | | 70-79yr | | 80yr- | | Total | |
|---|--------|---------|-----|---------|-----|---------|------|---------|------|-------|------|-------|-----|
| | | N | % | N | % | N | % | N | % | N | % | N | % |
| General anesthetic | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Hypnotic sedative agent, antianxiety agent | Male | 10 | 3.6 | 7 | 2.4 | 11 | 4.0 | 21 | 7.4 | 7 | 9.5 | 56 | 4.7 |
| | Female | 3 | 1.0 | 9 | 3.2 | 28 | 10.0 | 45 | 16.2 | 17 | 19.3 | 102 | 8.4 |
| | Total | 13 | 2.3 | 16 | 2.8 | 39 | 7.0 | 66 | 11.7 | 24 | 14.8 | 158 | 6.5 |

| | | | | | | | | | | | | | |
|--|--------|-----|------|-----|------|-----|------|-----|------|----|------|-----|------|
| Antiepileptic agent | Male | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 4 | 1.4 | 0 | 0.0 | 6 | 0.5 |
| | Female | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 2 | 0.7 | 2 | 2.3 | 6 | 0.5 |
| | Total | 1 | 0.2 | 0 | 0.0 | 3 | 0.5 | 6 | 1.1 | 2 | 1.2 | 12 | 0.5 |
| Antipyretic analgesic agent | Male | 26 | 9.3 | 30 | 10.4 | 32 | 11.7 | 58 | 20.4 | 31 | 41.9 | 177 | 14.8 |
| | Female | 53 | 18.0 | 56 | 20.2 | 42 | 14.9 | 65 | 23.4 | 29 | 33.0 | 245 | 20.1 |
| | Total | 79 | 13.8 | 86 | 15.2 | 74 | 13.3 | 123 | 21.9 | 60 | 37.0 | 422 | 17.4 |
| Stimulant drug, antihypnotic drug | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Antiparkinson drug | Male | 0 | 0.0 | 0 | 0.0 | 3 | 1.1 | 4 | 1.4 | 0 | 0.0 | 7 | 0.6 |
| | Female | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 2 | 0.2 |
| | Total | 0 | 0.0 | 1 | 0.2 | 3 | 0.5 | 5 | 0.9 | 0 | 0.0 | 9 | 0.4 |
| Antipsychotic drug | Male | 9 | 3.2 | 5 | 1.7 | 13 | 4.7 | 12 | 4.2 | 4 | 5.4 | 43 | 3.6 |
| | Female | 5 | 1.7 | 8 | 2.9 | 15 | 5.3 | 30 | 10.8 | 10 | 11.4 | 68 | 5.6 |
| | Total | 14 | 2.4 | 13 | 2.3 | 28 | 5.0 | 42 | 7.5 | 14 | 8.6 | 111 | 4.6 |
| Drugs for common cold | Male | 31 | 11.1 | 17 | 5.9 | 11 | 4.0 | 17 | 6.0 | 3 | 4.1 | 79 | 6.6 |
| | Female | 29 | 9.8 | 30 | 10.8 | 10 | 3.6 | 16 | 5.8 | 2 | 2.3 | 87 | 7.1 |
| | Total | 60 | 10.5 | 47 | 8.3 | 21 | 3.8 | 33 | 5.9 | 5 | 3.1 | 166 | 6.9 |
| Other agents acting on central nervous system | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 2 | 2.7 | 4 | 0.3 |
| | Female | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 3 | 3.4 | 5 | 0.4 |
| | Total | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 3 | 0.5 | 5 | 3.1 | 9 | 0.4 |
| Local anesthetic | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| | Total | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Muscle relaxant | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Agents acting on autonomic nervous system | Male | 0 | 0.0 | 1 | 0.3 | 1 | 0.4 | 1 | 0.4 | 0 | 0.0 | 3 | 0.3 |
| | Female | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 1 | 1.1 | 3 | 0.2 |
| | Total | 0 | 0.0 | 2 | 0.4 | 1 | 0.2 | 2 | 0.4 | 1 | 0.6 | 6 | 0.2 |
| Antispasmodic agent | Male | 0 | 0.0 | 2 | 0.7 | 3 | 1.1 | 4 | 1.4 | 1 | 1.4 | 10 | 0.8 |
| | Female | 4 | 1.4 | 2 | 0.7 | 3 | 1.1 | 5 | 1.8 | 3 | 3.4 | 17 | 1.4 |
| | Total | 4 | 0.7 | 4 | 0.7 | 6 | 1.1 | 9 | 1.6 | 4 | 2.5 | 27 | 1.1 |
| Antiperspirants | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other agents acting on peripheral nervous system | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Ophthalmic solution (others) | Male | 53 | 19.0 | 58 | 20.1 | 51 | 18.6 | 72 | 25.4 | 23 | 31.1 | 257 | 21.4 |
| | Female | 56 | 19.0 | 64 | 23.1 | 85 | 30.2 | 99 | 35.6 | 42 | 47.7 | 346 | 28.4 |
| | Total | 109 | 19.0 | 122 | 21.6 | 136 | 24.5 | 171 | 30.4 | 65 | 40.1 | 603 | 24.9 |
| Ophthalmic solution (for cataract) | Male | 0 | 0.0 | 2 | 0.7 | 14 | 5.1 | 32 | 11.3 | 8 | 10.8 | 56 | 4.7 |
| | Female | 1 | 0.3 | 8 | 2.9 | 22 | 7.8 | 50 | 18.0 | 16 | 18.2 | 97 | 8.0 |
| | Total | 1 | 0.2 | 10 | 1.8 | 36 | 6.5 | 82 | 14.6 | 24 | 14.8 | 153 | 6.3 |
| Ophthalmic solution (pilocarpine) | Male | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 1 | 0.4 | 0 | 0.0 | 2 | 0.2 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.1 |
| | Total | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 0 | 0.0 | 3 | 0.1 |
| Ophthalmic solution (β blocker) | Male | 3 | 1.1 | 2 | 0.7 | 8 | 2.9 | 10 | 3.5 | 4 | 5.4 | 27 | 2.3 |

| | | | | | | | | | | | | | |
|--|--------|---|-----|----|-----|----|-----|----|-----|----|-----|----|-----|
| | Female | 0 | 0.0 | 2 | 0.7 | 3 | 1.1 | 7 | 2.5 | 5 | 5.7 | 17 | 1.4 |
| | Total | 3 | 0.5 | 4 | 0.7 | 11 | 2.0 | 17 | 3.0 | 9 | 5.6 | 44 | 1.8 |
| Ophthalmic solution (epinephrine) | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Ophthalmic solution (other solutions for glaucoma) | Male | 2 | 0.7 | 1 | 0.3 | 11 | 4.0 | 14 | 4.9 | 4 | 5.4 | 32 | 2.7 |
| | Female | 2 | 0.7 | 3 | 1.1 | 4 | 1.4 | 10 | 3.6 | 1 | 1.1 | 20 | 1.6 |
| | Total | 4 | 0.7 | 4 | 0.7 | 15 | 2.7 | 24 | 4.3 | 5 | 3.1 | 52 | 2.1 |
| Ophthalmic solution (steroid) | Male | 2 | 0.7 | 4 | 1.4 | 5 | 1.8 | 11 | 3.9 | 4 | 5.4 | 26 | 2.2 |
| | Female | 2 | 0.7 | 5 | 1.8 | 12 | 4.3 | 17 | 6.1 | 7 | 8.0 | 43 | 3.5 |
| | Total | 4 | 0.7 | 9 | 1.6 | 17 | 3.1 | 28 | 5.0 | 11 | 6.8 | 69 | 2.9 |
| Ophthalmic solution (unknown) | Male | 0 | 0.0 | 1 | 0.3 | 1 | 0.4 | 2 | 0.7 | 2 | 2.7 | 6 | 0.5 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 4 | 1.4 | 0 | 0.0 | 4 | 0.3 |
| | Total | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 6 | 1.1 | 2 | 1.2 | 10 | 0.4 |
| Agents acting on ear, nose and throat use | Male | 0 | 0.0 | 3 | 1.0 | 1 | 0.4 | 2 | 0.7 | 2 | 2.7 | 8 | 0.7 |
| | Female | 1 | 0.3 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 1.1 | 3 | 0.2 |
| | Total | 1 | 0.2 | 4 | 0.7 | 1 | 0.2 | 2 | 0.4 | 3 | 1.9 | 11 | 0.5 |
| Anti-vertigenous drug | Male | 3 | 1.1 | 2 | 0.7 | 3 | 1.1 | 3 | 1.1 | 1 | 1.4 | 12 | 1.0 |
| | Female | 1 | 0.3 | 1 | 0.4 | 4 | 1.4 | 8 | 2.9 | 2 | 2.3 | 16 | 1.3 |
| | Total | 4 | 0.7 | 3 | 0.5 | 7 | 1.3 | 11 | 2.0 | 3 | 1.9 | 28 | 1.2 |
| Other agents acting on sensory organ | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Digitalis agent | Male | 0 | 0.0 | 0 | 0.0 | 4 | 1.5 | 3 | 1.1 | 5 | 6.8 | 12 | 1.0 |
| | Female | 0 | 0.0 | 2 | 0.7 | 1 | 0.4 | 2 | 0.7 | 3 | 3.4 | 8 | 0.7 |
| | Total | 0 | 0.0 | 2 | 0.4 | 5 | 0.9 | 5 | 0.9 | 8 | 4.9 | 20 | 0.8 |
| Xanthine agent | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| | Total | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Other inotropic agents | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 2.7 | 2 | 0.2 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.1 | 1 | 0.1 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 1.9 | 3 | 0.1 |
| β blocker | Male | 2 | 0.7 | 10 | 3.5 | 14 | 5.1 | 18 | 6.3 | 3 | 4.1 | 47 | 3.9 |
| | Female | 2 | 0.7 | 10 | 3.6 | 7 | 2.5 | 20 | 7.2 | 3 | 3.4 | 42 | 3.4 |
| | Total | 4 | 0.7 | 20 | 3.5 | 21 | 3.8 | 38 | 6.8 | 6 | 3.7 | 89 | 3.7 |
| Agents for membrane-stabilizing activity | Male | 1 | 0.4 | 1 | 0.3 | 1 | 0.4 | 4 | 1.4 | 2 | 2.7 | 9 | 0.8 |
| | Female | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 5 | 1.8 | 1 | 1.1 | 8 | 0.7 |
| | Total | 1 | 0.2 | 1 | 0.2 | 3 | 0.5 | 9 | 1.6 | 3 | 1.9 | 17 | 0.7 |
| Other antiarrhythmic agents | Male | 0 | 0.0 | 1 | 0.3 | 1 | 0.4 | 2 | 0.7 | 1 | 1.4 | 5 | 0.4 |
| | Female | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 2 | 0.7 | 0 | 0.0 | 3 | 0.2 |
| | Total | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 4 | 0.7 | 1 | 0.6 | 8 | 0.3 |
| Thiazide diuretics | Male | 1 | 0.4 | 2 | 0.7 | 2 | 0.7 | 1 | 0.4 | 1 | 1.4 | 7 | 0.6 |
| | Female | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 10 | 3.6 | 8 | 9.1 | 20 | 1.6 |
| | Total | 1 | 0.2 | 2 | 0.4 | 4 | 0.7 | 11 | 2.0 | 9 | 5.6 | 27 | 1.1 |
| Loop diuretics | Male | 1 | 0.4 | 1 | 0.3 | 2 | 0.7 | 9 | 3.2 | 7 | 9.5 | 20 | 1.7 |
| | Female | 0 | 0.0 | 2 | 0.7 | 3 | 1.1 | 7 | 2.5 | 6 | 6.8 | 18 | 1.5 |
| | Total | 1 | 0.2 | 3 | 0.5 | 5 | 0.9 | 16 | 2.8 | 13 | 8.0 | 38 | 1.6 |
| Potassium sparing diuretics | Male | 0 | 0.0 | 1 | 0.3 | 2 | 0.7 | 2 | 0.7 | 1 | 1.4 | 6 | 0.5 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 3 | 3.4 | 5 | 0.4 |
| | Total | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 4 | 0.7 | 4 | 2.5 | 11 | 0.5 |

| | | | | | | | | | | | | | |
|---|--------|----|-----|----|------|----|------|-----|------|----|------|-----|------|
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other agents acting on respiratory system | Male | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 1 | 0.4 | 1 | 1.4 | 4 | 0.3 |
| | Female | 0 | 0.0 | 1 | 0.4 | 1 | 0.4 | 2 | 0.7 | 0 | 0.0 | 4 | 0.3 |
| | Total | 0 | 0.0 | 1 | 0.2 | 3 | 0.5 | 3 | 0.5 | 1 | 0.6 | 8 | 0.3 |
| Antidiarrheal agent | Male | 9 | 3.2 | 4 | 1.4 | 9 | 3.3 | 8 | 2.8 | 5 | 6.8 | 35 | 2.9 |
| | Female | 6 | 2.0 | 1 | 0.4 | 11 | 3.9 | 9 | 3.2 | 10 | 11.4 | 37 | 3.0 |
| | Total | 15 | 2.6 | 5 | 0.9 | 20 | 3.6 | 17 | 3.0 | 15 | 9.3 | 72 | 3.0 |
| Antiulcerative agent | Male | 14 | 5.0 | 23 | 8.0 | 34 | 12.4 | 61 | 21.5 | 21 | 28.4 | 153 | 12.8 |
| | Female | 13 | 4.4 | 29 | 10.5 | 31 | 11.0 | 66 | 23.7 | 32 | 36.4 | 171 | 14.0 |
| | Total | 27 | 4.7 | 52 | 9.2 | 65 | 11.7 | 127 | 22.6 | 53 | 32.7 | 324 | 13.4 |
| Stomachic | Male | 1 | 0.4 | 1 | 0.3 | 4 | 1.5 | 6 | 2.1 | 5 | 6.8 | 17 | 1.4 |
| | Female | 0 | 0.0 | 3 | 1.1 | 2 | 0.7 | 5 | 1.8 | 6 | 6.8 | 16 | 1.3 |
| | Total | 1 | 0.2 | 4 | 0.7 | 6 | 1.1 | 11 | 2.0 | 11 | 6.8 | 33 | 1.4 |
| Antacid | Male | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 0 | 0.0 | 0 | 0.0 | 2 | 0.2 |
| | Female | 1 | 0.3 | 0 | 0.0 | 2 | 0.7 | 2 | 0.7 | 1 | 1.1 | 6 | 0.5 |
| | Total | 1 | 0.2 | 0 | 0.0 | 4 | 0.7 | 2 | 0.4 | 1 | 0.6 | 8 | 0.3 |
| Laxative | Male | 3 | 1.1 | 3 | 1.0 | 5 | 1.8 | 13 | 4.6 | 12 | 16.2 | 36 | 3.0 |
| | Female | 6 | 2.0 | 16 | 5.8 | 7 | 2.5 | 23 | 8.3 | 10 | 11.4 | 62 | 5.1 |
| | Total | 9 | 1.6 | 19 | 3.4 | 12 | 2.2 | 36 | 6.4 | 22 | 13.6 | 98 | 4.1 |
| Cholagogue | Male | 1 | 0.4 | 2 | 0.7 | 8 | 2.9 | 5 | 1.8 | 2 | 2.7 | 18 | 1.5 |
| | Female | 1 | 0.3 | 2 | 0.7 | 1 | 0.4 | 1 | 0.4 | 0 | 0.0 | 5 | 0.4 |
| | Total | 2 | 0.3 | 4 | 0.7 | 9 | 1.6 | 6 | 1.1 | 2 | 1.2 | 23 | 1.0 |
| Combined digestive agent | Male | 5 | 1.8 | 16 | 5.5 | 8 | 2.9 | 10 | 3.5 | 2 | 2.7 | 41 | 3.4 |
| | Female | 9 | 3.1 | 5 | 1.8 | 10 | 3.6 | 4 | 1.4 | 2 | 2.3 | 30 | 2.5 |
| | Total | 14 | 2.4 | 21 | 3.7 | 18 | 3.2 | 14 | 2.5 | 4 | 2.5 | 71 | 2.9 |
| Other agents acting on alimentary system | Male | 1 | 0.4 | 1 | 0.3 | 6 | 2.2 | 8 | 2.8 | 5 | 6.8 | 21 | 1.8 |
| | Female | 4 | 1.4 | 1 | 0.4 | 3 | 1.1 | 14 | 5.0 | 9 | 10.2 | 31 | 2.5 |
| | Total | 5 | 0.9 | 2 | 0.4 | 9 | 1.6 | 22 | 3.9 | 14 | 8.6 | 52 | 2.1 |
| Pituitary hormone drug | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Hormone drug of salivary gland | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.1 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 1 | 0.0 |
| Thyroid hormone or parathyroid hormone drug | Male | 0 | 0.0 | 2 | 0.7 | 1 | 0.4 | 1 | 0.4 | 2 | 2.7 | 6 | 0.5 |
| | Female | 3 | 1.0 | 8 | 2.9 | 5 | 1.8 | 7 | 2.5 | 2 | 2.3 | 25 | 2.1 |
| | Total | 3 | 0.5 | 10 | 1.8 | 6 | 1.1 | 8 | 1.4 | 4 | 2.5 | 31 | 1.3 |
| Anabolic steroid drug | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Adrenocortical hormone drug | Male | 2 | 0.7 | 3 | 1.0 | 4 | 1.5 | 11 | 3.9 | 0 | 0.0 | 20 | 1.7 |
| | Female | 2 | 0.7 | 7 | 2.5 | 10 | 3.6 | 6 | 2.2 | 3 | 3.4 | 28 | 2.3 |
| | Total | 4 | 0.7 | 10 | 1.8 | 14 | 2.5 | 17 | 3.0 | 3 | 1.9 | 48 | 2.0 |
| Androgen drug | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Estrogen or progesterone drug | Male | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 2 | 0.7 | 0 | 0.0 | 3 | 0.3 |
| | Female | 3 | 1.0 | 2 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 5 | 0.4 |
| | Total | 3 | 0.5 | 2 | 0.4 | 1 | 0.2 | 2 | 0.4 | 0 | 0.0 | 8 | 0.3 |

| | | | | | | | | | | | | | |
|--|--------|----|-----|----|-----|----|-----|----|-----|----|------|-----|-----|
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Steroid surface-acting agent | Male | 10 | 3.6 | 14 | 4.8 | 16 | 5.8 | 14 | 4.9 | 2 | 2.7 | 56 | 4.7 |
| | Female | 15 | 5.1 | 15 | 5.4 | 21 | 7.5 | 7 | 2.5 | 6 | 6.8 | 64 | 5.3 |
| | Total | 25 | 4.4 | 29 | 5.1 | 37 | 6.7 | 21 | 3.7 | 8 | 4.9 | 120 | 5.0 |
| Dental local anesthetic | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Agents for devitalization of the pulp | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Analgesic or sedative for dental use | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Agents for mummification of the pulp | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Agents for pulp capping | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Antibiotics for dental use | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other agents for dental use | Male | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 2 | 0.2 |
| | Female | 1 | 0.3 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 2 | 0.2 |
| | Total | 2 | 0.3 | 0 | 0.0 | 0 | 0.0 | 2 | 0.4 | 0 | 0.0 | 4 | 0.2 |
| Other agents for organ system | Male | 0 | 0.0 | 1 | 0.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Vitamin A preparation | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Vitamin D preparation | Male | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 4 | 1.4 | 1 | 1.4 | 7 | 0.6 |
| | Female | 1 | 0.3 | 1 | 0.4 | 12 | 4.3 | 23 | 8.3 | 11 | 12.5 | 48 | 3.9 |
| | Total | 2 | 0.3 | 1 | 0.2 | 13 | 2.3 | 27 | 4.8 | 12 | 7.4 | 55 | 2.3 |
| Vitamin B1 preparation | Male | 0 | 0.0 | 1 | 0.3 | 2 | 0.7 | 2 | 0.7 | 2 | 2.7 | 7 | 0.6 |
| | Female | 1 | 0.3 | 0 | 0.0 | 0 | 0.0 | 4 | 1.4 | 1 | 1.1 | 6 | 0.5 |
| | Total | 1 | 0.2 | 1 | 0.2 | 2 | 0.4 | 6 | 1.1 | 3 | 1.9 | 13 | 0.5 |
| Vitamin B complex preparation (exclude B1) | Male | 4 | 1.4 | 6 | 2.1 | 10 | 3.6 | 19 | 6.7 | 9 | 12.2 | 48 | 4.0 |
| | Female | 6 | 2.0 | 6 | 2.2 | 7 | 2.5 | 17 | 6.1 | 12 | 13.6 | 48 | 3.9 |
| | Total | 10 | 1.7 | 12 | 2.1 | 17 | 3.1 | 36 | 6.4 | 21 | 13.0 | 96 | 4.0 |
| Vitamin C preparation | Male | 0 | 0.0 | 1 | 0.3 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 2 | 0.2 |
| | Female | 1 | 0.3 | 1 | 0.4 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 3 | 0.2 |
| | Total | 1 | 0.2 | 2 | 0.4 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 5 | 0.2 |
| Vitamin E preparation | Male | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| | Female | 0 | 0.0 | 1 | 0.4 | 1 | 0.4 | 0 | 0.0 | 1 | 1.1 | 3 | 0.2 |
| | Total | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 0 | 0.0 | 1 | 0.6 | 4 | 0.2 |
| Vitamin K preparation | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.1 |
| | Female | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 1 | 0.4 | 5 | 5.7 | 7 | 0.6 |
| | Total | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 5 | 3.1 | 8 | 0.3 |

| | | | | | | | | | | | | | |
|---|--------|----|-----|----|-----|----|-----|----|-----|---|-----|-----|-----|
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Agents for liver disease | Male | 0 | 0.0 | 0 | 0.0 | 3 | 1.1 | 4 | 1.4 | 0 | 0.0 | 7 | 0.6 |
| | Female | 1 | 0.3 | 0 | 0.0 | 3 | 1.1 | 1 | 0.4 | 3 | 3.4 | 8 | 0.7 |
| | Total | 1 | 0.2 | 0 | 0.0 | 6 | 1.1 | 5 | 0.9 | 3 | 1.9 | 15 | 0.6 |
| Antidote | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.1 |
| | Female | 1 | 0.3 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 1.1 | 3 | 0.2 |
| | Total | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 1 | 0.6 | 4 | 0.2 |
| Agents for habitual intoxication | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Agents for gout | Male | 10 | 3.6 | 11 | 3.8 | 16 | 5.8 | 28 | 9.9 | 5 | 6.8 | 70 | 5.8 |
| | Female | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 7 | 2.5 | 2 | 2.3 | 10 | 0.8 |
| | Total | 10 | 1.7 | 12 | 2.1 | 16 | 2.9 | 35 | 6.2 | 7 | 4.3 | 80 | 3.3 |
| Enzyme preparation | Male | 1 | 0.4 | 1 | 0.3 | 5 | 1.8 | 4 | 1.4 | 2 | 2.7 | 13 | 1.1 |
| | Female | 2 | 0.7 | 3 | 1.1 | 1 | 0.4 | 2 | 0.7 | 0 | 0.0 | 8 | 0.7 |
| | Total | 3 | 0.5 | 4 | 0.7 | 6 | 1.1 | 6 | 1.1 | 2 | 1.2 | 21 | 0.9 |
| Insulin | Male | 0 | 0.0 | 1 | 0.3 | 4 | 1.5 | 6 | 2.1 | 0 | 0.0 | 11 | 0.9 |
| | Female | 1 | 0.3 | 2 | 0.7 | 3 | 1.1 | 2 | 0.7 | 0 | 0.0 | 8 | 0.7 |
| | Total | 1 | 0.2 | 3 | 0.5 | 7 | 1.3 | 8 | 1.4 | 0 | 0.0 | 19 | 0.8 |
| Oral antidiabetics | Male | 2 | 0.7 | 15 | 5.2 | 19 | 6.9 | 21 | 7.4 | 6 | 8.1 | 63 | 5.3 |
| | Female | 5 | 1.7 | 5 | 1.8 | 13 | 4.6 | 22 | 7.9 | 2 | 2.3 | 47 | 3.9 |
| | Total | 7 | 1.2 | 20 | 3.5 | 32 | 5.8 | 43 | 7.7 | 8 | 4.9 | 110 | 4.5 |
| Agents acting generally on metabolic system | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unclassified agent acting on metabolic system | Male | 3 | 1.1 | 3 | 1.0 | 3 | 1.1 | 5 | 1.8 | 1 | 1.4 | 15 | 1.3 |
| | Female | 2 | 0.7 | 3 | 1.1 | 0 | 0.0 | 5 | 1.8 | 3 | 3.4 | 13 | 1.1 |
| | Total | 5 | 0.9 | 6 | 1.1 | 3 | 0.5 | 10 | 1.8 | 4 | 2.5 | 28 | 1.2 |
| Calcitonin (elcatonin) | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 3.4 | 3 | 0.2 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 1.9 | 3 | 0.1 |
| Calcitonin (calcitonin salmon) | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Bisphosphonate (alendronate sodium hydrate) | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.1 |
| | Female | 0 | 0.0 | 1 | 0.4 | 6 | 2.1 | 7 | 2.5 | 5 | 5.7 | 19 | 1.6 |
| | Total | 0 | 0.0 | 1 | 0.2 | 6 | 1.1 | 8 | 1.4 | 5 | 3.1 | 20 | 0.8 |
| Bisphosphonate (sodium risedronate hydrate) | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 2 | 0.7 | 0 | 0.0 | 5 | 1.8 | 7 | 2.5 | 1 | 1.1 | 15 | 1.2 |
| | Total | 2 | 0.3 | 0 | 0.0 | 5 | 0.9 | 7 | 1.2 | 1 | 0.6 | 15 | 0.6 |
| Bisphosphonate (etidronate disodium) | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 1 | 0.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| | Total | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Ipriflavone | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Selective estrogen receptor modulator | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 3 | 1.1 | 3 | 1.1 | 1 | 1.1 | 7 | 0.6 |
| | Total | 0 | 0.0 | 0 | 0.0 | 3 | 0.5 | 3 | 0.5 | 1 | 0.6 | 7 | 0.3 |

| | | | | | | | | | | | | | |
|-----------------------|--------|-----|-------|-----|-------|-----|-------|-----|-------|-----|-------|------|-------|
| Other alkaloid agents | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Synthetic narcotic | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unclassifiable drug | Male | 1 | 0.4 | 1 | 0.3 | 1 | 0.4 | 2 | 0.7 | 0 | 0.0 | 5 | 0.4 |
| | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 | 2 | 2.3 | 4 | 0.3 |
| | Total | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 4 | 0.7 | 2 | 1.2 | 9 | 0.4 |
| No use of drug | Male | 121 | 43.4 | 104 | 36.0 | 77 | 28.1 | 42 | 14.8 | 8 | 10.8 | 352 | 29.3 |
| | Female | 118 | 40.0 | 81 | 29.2 | 65 | 23.1 | 26 | 9.4 | 5 | 5.7 | 295 | 24.2 |
| | Total | 239 | 41.6 | 185 | 32.7 | 142 | 25.6 | 68 | 12.1 | 13 | 8.0 | 647 | 26.7 |
| Total | Male | 279 | 100.0 | 289 | 100.0 | 274 | 100.0 | 284 | 100.0 | 74 | 100.0 | 1200 | 100.0 |
| | Female | 295 | 100.0 | 277 | 100.0 | 281 | 100.0 | 278 | 100.0 | 88 | 100.0 | 1219 | 100.0 |
| | Total | 574 | 100.0 | 566 | 100.0 | 555 | 100.0 | 562 | 100.0 | 162 | 100.0 | 2419 | 100.0 |